RICHARD KAHNOSKI, MD
Urology in Grand Rapids, MI

License number
Michigan 4301043361
Category
Radiology
Type
Urology
Address
Address
4069 Se S-313, Grand Rapids, MI 49546
Phone
(616) 774-9333

Professional information

Richard J Kahnoski Photo 1

Dr. Richard J Kahnoski, Grand Rapids MI - MD (Doctor of Medicine)

Specialties:
Urology
Address:
Michigan Medical PC Urology
4069 Lake Dr SE STE 313, Grand Rapids 49546
(616) 774-9333 (Phone)
Certifications:
Urology, 1988
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Hospitals:
Michigan Medical PC Urology
4069 Lake Dr SE STE 313, Grand Rapids 49546
Spectrum Health- Butterworth Hospital
100 Michigan St North #East, Grand Rapids 49503
Spectum Health - Blodgett Hospital
1840 Wealthy St South #East, Grand Rapids 49506
Spectrum Health United Hospital
615 South Bower St, Greenville 48838
Education:
Medical School
Michigan State University College Of Human Medicine
Graduated: 1979
Butterworth Hospital
Graduated: 1980
Indiana University School Of Med
Graduated: 1982


Richard J Kahnoski Photo 2

Richard J Kahnoski, Grand Rapids MI

Specialties:
Urology, Adult Medicine, Medical Oncology
Work:
Shmg - Gr
4069 Lake Dr SE, Grand Rapids, MI 49546 Spectrum Health Medical Center
145 Michigan St NE, Grand Rapids, MI 49503
Education:
Michigan State University(1979)


Richard Kahnoski Photo 3

Methods For Treating Sunitinib-Resistant Carcinoma And Related Biomarkers

US Patent:
2009028, Nov 19, 2009
Filed:
May 15, 2009
Appl. No.:
12/466951
Inventors:
Bin Tean Teh - Grand Rapids MI, US
Kyle Furge - Kalamazoo MI, US
Dan Huang - Ada MI, US
Richard Kahnoski - Grand Rapids MI, US
International Classification:
A61K 31/404, A61P 35/00, A61K 39/395, A61K 31/7088, G01N 33/53, C12Q 1/68
US Classification:
4241581, 514414, 514 44 A, 435 71, 435 6
Abstract:
A method of determining whether a tumor will be non-responsive to sunitinib therapy including detecting whether IL-8 or MMP12 expression levels in the tumor are elevated as compared to a control, that is, a tumor having elevated IL-8 or MMP12 levels will be non-responsive to sunitinib. Also, a method for inhibiting the proliferation or causing the death of a sunitinib-resistant tumor cell by contacting the cell with an agent that inhibits IL-8 or MMP12 activity and with sunitinib, whereby proliferation of the tumor cell is inhibited or the tumor cell dies. Further, the invention includes compositions and kits that include an IL-8 inhibitor or an MMP12 inhibitor and sunitinib, and related methods of treatment.